Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I a Randomized,Double-Blind, Placebo-controlled Clinical Trial to Preliminary Evaluate the Safety and Immunogenicity of Protein Based Pneumococcal VaccinePBPV in Healthy People Aged Between 18 and 49 Years Old

Next Previous
Trial Profile

A Phase I a Randomized,Double-Blind, Placebo-controlled Clinical Trial to Preliminary Evaluate the Safety and Immunogenicity of Protein Based Pneumococcal VaccinePBPV in Healthy People Aged Between 18 and 49 Years Old

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal vaccine (Primary)
  • Indications Pneumococcal infections; Respiratory tract infections
  • Focus Adverse reactions
  • Acronyms PICTPV
  • Sponsors Tianjin CanSino Biotechnology

Most Recent Events

  • 28 Oct 2022 Status changed from active, no longer recruiting to completed.
  • 10 Nov 2020 Planned primary completion date changed from 30 Dec 2020 to 30 May 2021.
  • 04 Aug 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top